SARS-CoV-2 infection in patients with cancer: analyzing the pandemic outcomes
DOI: 10.32364/2587-6821-2025-9-7-7
I.D. Kanner, D.V. Usenko
Central Research Institute of Epidemiology of the Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russian Federation
The COVID-19 pandemic has constituted one of the most significant challenges to global healthcare and the international community in recent decades. Particular concern has been raised regarding the situation of the most vulnerable population groups, among which patients with oncological diseases are of paramount importance. Investigation of the COVID-19 clinical course in patients with cancer, as well as the optimization of patient management during the pandemic, represent critical areas of contemporary medicine. This review analyzes the findings of studies on the COVID-19 course among oncological patients. It demonstrates the gradual and dynamic evolution of both scientific and clinical understanding of this issue. From the initial alarming case reports in 2020 to systemic analyses of long-term outcomes in the period from 2023 to 2025, the medical and scientific communities have exhibited the capacity for rapid response to challenges posed by the novel coronavirus infection. During these years, effective clinical guidelines have been developed to provide a balance between the necessity of continuing antitumor therapy and minimizing the risk of SARS-CoV-2 infection. Currently, active study on the clinical and laboratory patterns of coronavirus infection in oncological patients is ongoing.
Keywords: oncology, COVID-19, SARS-CoV-2 infection, pandemic, vulnerable populations, vaccination, antitumor therapy.
For citation: Kanner I.D., Usenko D.V. SARS-CoV-2 infection in patients with cancer: analyzing the pandemic outcomes. Russian Medical Inquiry. 2025;9(7):413–418 (in Russ.). DOI: 10.32364/2587-6821-2025-9-7-7
About the authors:
Ilya D. Kanner — post-graduate student of the Central Research Institute of Epidemiology of the Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being; 3A, Novogireevskaya str., Moscow, 111123, Russian Federation; ORCID iD 0000-0003-4632-0547
Denis V. Usenko— Dr. Sc. (Med.), Senior Researcher at the Clinical Department of Infectious Pathology, Central Research Institute of Epidemiology of the Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being; 3A, Novogireevskaya str., Moscow, 111123, Russia; ORCID iD 0000-0001-5232-7337
Contact information: Ilya D. Kanner, e-mail: dwilya4@mail.ru
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 27.05.2025.
Revised 23.06.2025.
Accepted 16.07.2025.
2. Zhu N., Zhang D., Wang W. et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. DOI: 10.1056/NEJMoa2001017
3. Dai M., Liu D., Liu M. et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multi-center study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783–791. DOI: 10.1158/2159-8290.CD-20-0422
4. Kuderer N.M., Choueiri T.K., Shah D.P. et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907–1918. DOI: 10.1016/S0140-6736(20)31187-9
5. Cortellini A., Dettorre G.M., Dafni U. et al. Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries. J Immunother Cancer. 2022;10:e005732. DOI: 10.1136/jitc-2022-005732
6. Wang C., Horby P.W., Hayden F.G., Gao G.F. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470–473. DOI: 10.1016/S0140-6736(20)30185-9
7. Lee L.Y.W., Cazier J.B., Angelis V. et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395(10241):1919–1926. DOI: 10.1016/S0140-6736(20)31173-9
8. ElGohary G.M., Hashmi S., Styczynski J. et al. The Risk and Prognosis of COVID-19 Infection in Cancer Patients: A Systematic Review and Meta-Analysis. Hematol Oncol Stem Cell Ther. 2022;15(2):45–53. DOI: 10.1016/j.hemonc.2020.07.005
9. ASCO. A guide to cancer care delivery during the COVID-19 pandemic. Alexandria (VA): American Society of Clinical Oncology; 2020.
10. Hanna T.P., Evans G.A., Booth C.M. Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. Nat Rev Clin Oncol. 2020;17(5):268–270. DOI: 10.1038/s41571-020-0362-6
11. ESMO. Cancer patient management during the COVID-19 pandemic. Lugano: European Society for Medical Oncology; 2020.
12. ESMO Guidelines Committee. Cancer patient management during the COVID-19 pandemic. ESMO; 2020.
13. Grivas P., Khaki A.R., Wise-Draper T.M. et al. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol. 2021;32(6):787–800. DOI: 10.1016/j.annonc.2021.02.024
14. Jee J., Foote M.B., Lumish M. et al. Chemotherapy and COVID-19 outcomes in patients with cancer. J Clin Oncol. 2022;40(7):694–705. DOI: 10.1200/JCO.20.01307
15. Liang W., Guan W., Chen R. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–337. DOI: 10.1016/S1470-2045(20)30096-6
16. Ofori-Asenso R., Ogundipe O., Agyeman A.A. et al. Cancer is associated with severe disease in COVID-19 patients: a systematic review and meta-analysis. Ecancermedicalscience. 2020;14:1047. DOI: 10.3332/ecancer.2020.1047
17. Passamonti F., Cattaneo C., Arcaini L. et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with hematologic malignancies in Italy: a retrospective, multicenter, cohort study. Lancet Haematol. 2020;7(10):e737–e745. DOI: 10.1016/S2352-3026(20)30251-9
18. Curigliano G., Banerjee S., Cervantes A. et al. Managing cancer patients during the COVID-19 pandemic: an ESMO interdisciplinary expert consensus. Ann Oncol. 2020;31(10):1320–1335. DOI: 10.1016/j.annonc.2020.07.010
19. Al-Shamsi H.O., Alhazzani W., Alhuraiji A. et al. A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: an international collaborative group. Oncologist. 2020;25(6):e936–e945. DOI: 10.1634/theoncologist.2020-0213
20. Fendler A., Shepherd S.T.C., Au L. et al. Adaptive immunity and antibody response to SARS-CoV-2 in cancer patients: the CAPTURE study. Lancet Oncol. 2022;23(6):740–752. DOI: 10.1038/s43018-021-00274-w
21. Monin L., Laing A.G., Muñoz-Ruiz M. et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22(6):765–778. DOI: 10.1016/S1470-2045(21)00213-8
22. Thakkar A., Gonzalez-Lugo J.D., Goradia N. et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell. 2021;39(8):1081–1090. DOI: 10.1016/j.ccell.2021.06.002
23. Greenberger L.M., Saltzman L.A., Senefeld J.W. et al. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell. 2021;39(8):1031–1033. DOI: 10.1016/j.ccell.2021.07.012
24. Terpos E., Trougakos I.P., Gavriatopoulou M. et al. Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. Blood. 2021;137(26):3674–3676. DOI: 10.1182/blood.2021011904
25. Herishanu Y., Avivi I., Aharon A. et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137(23):3165–3173. DOI: 10.1182/blood.2021011568
26. Levin M.J., Ustianowski A., De Wit S. et al. Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for prevention of COVID-19. N Engl J Med. 2022;386:2188–2200. DOI: 10.1056/NEJMoa2116620
27. Montgomery H., Hobbs F.D.R., Padilla F. et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2022;10(10):985–996. DOI: 10.3390/diseases10040118
28. Naranbhai V., Garcia-Beltran W.F., Chang C.C. et al. Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines. Nat Med. 2021;225(7):1141–1150. DOI: 10.1101/2021.07.18.21260732
29. Cavanna L., Citterio C., Toscani I. COVID-19 vaccines in cancer patients. Cancer Treat Rev. 2021;98:102223. DOI: 10.1016/S1470-2045(21)00250-3
30. Al-Aly Z., Xie Y., Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259–264. DOI: 10.1038/s41586-021-03553-9
31. Sudre C.H., Murray B., Varsavsky T. et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626–631. DOI: 10.1038/s41591-021-01292-y
32. Maringe C., Spicer J., Morris M. et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England. Lancet Oncol. 2020;21(8):1023–1034. DOI: 10.1016/S1470-2045(20)30388-0
33. Kaufman H.W., Chen Z., Niles J., Fesko Y. Changes in the number of US patients with newly identified cancer before and during the Coronavirus Disease 2019 (COVID-19) pandemic. JAMA Netw Open. 2020;3(8):e2017267. DOI: 10.1001/jamanetworkopen.2020.17267
34. Agha M., Blake M., Chilleo C. et al. Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients. J Hematol Oncol. 2021;14(1):1–3. DOI: 10.1101/2021.04.06.21254949
35. Garcia-Beltran W.F., Lam E.C., Astudillo M.G. et al. COVID-19 neutralizing antibodies predict disease severity and survival. Cell. 2021;184(2):476–488.e11. DOI: 10.1101/2020.10.15.20213512
36. Bharat A., Bittner Z., Kim J. et al. SARS-CoV-2 RNA induces intratumoral monocyte-mediated immune activation and tumor regression. J Clin Invest. 2024;134(22):e171775. DOI: 10.1172/JCI171775.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
